Cystic Fibrosis
Vertex Pharmaceuticals Inc. maintains a major clinical focus on cystic fibrosis, with studies spanning long-term treatment evaluation and combination regimens built around CFTR modulator therapies. Research activity includes interest in both established and newer treatment approaches across a broad age range, including infants, children, adolescents, and adults.
- CFTR modulation
- Long-term safety
- Pediatric cystic fibrosis
- Combination therapy
Its cystic fibrosis portfolio reflects sustained attention to respiratory disease management and disease-modifying therapy development.
Genetic Haematology
The sponsor is actively engaged in sickle cell disease and transfusion-dependent beta-thalassemia, including research involving autologous CRISPR-Cas9 modified hematopoietic stem cells and other gene-based approaches. These programmes cover severe disease forms in both pediatric and adult populations.
- Sickle cell disease
- Transfusion-dependent beta-thalassemia
- Gene editing
- Haematopoietic stem cell therapy
Research in this area also includes follow-up interest in inherited blood disorders and treatment durability.
Type 1 Diabetes
Vertex Pharmaceuticals Inc. is studying type 1 diabetes mellitus, with particular emphasis on individuals with impaired hypoglycemic awareness and severe hypoglycemia. The trial landscape includes interest in cell-based approaches and functional restoration of insulin production.
- Type 1 diabetes mellitus
- Impaired hypoglycemic awareness
- Severe hypoglycemia
- Cell therapy
This area reflects a therapeutic focus on metabolic disease and advanced regenerative strategies.
Kidney and Renal Disease
The sponsor’s renal research includes APOL1-mediated proteinuric kidney disease, autosomal dominant polycystic kidney disease, and primary membranous nephropathy. These studies indicate interest in progressive kidney disorders linked to genetic risk, cystic disease, and immune-mediated renal injury.
- APOL1-mediated proteinuric kidney disease
- Autosomal dominant polycystic kidney disease
- Primary membranous nephropathy
- Proteinuria
Clinical activity in this domain is directed toward kidney function preservation and disease-specific treatment development.
Neuromuscular and Pain Disorders
Vertex Pharmaceuticals Inc. also supports research in myotonic dystrophy type 1 and pain associated with diabetic peripheral neuropathy. These programmes span neuromuscular disease and chronic neuropathic pain, addressing conditions with significant functional impact.
- Myotonic dystrophy type 1
- Diabetic peripheral neuropathy
- Neuromuscular disease
- Neuropathic pain
Its work in these areas extends the sponsor’s interest beyond metabolic and genetic disorders into neurological and pain-related therapeutics.
